Abstracts

Citation

Michael Boivin, Miriam Chernoff, , Bonnie Zimmer, Barbara Laughton, , Katie McCarthy, Pim Brouwers, Patrick Jean-Philippe, , , Avy Violari, Mark Cotton, Paul Palumbo, the P1104s Study Team. Neuropsychological performance of HIV-infected and uninfected African children. Presented at: 7th International Workshop on HIV Pediatrics 2015.

Citation

Elizabeth J. McFarland, Edmund V. Capparelli, Madeline Abbott, Camlin Tierney, Charlotte Perlowski, Mutsawashe Bwakura-Dangarembizi, Tsungai Mhembere, Hazzie Mvula, Patrick Jean-Philippe, Jack Moye, Diane Costello, Sarah Wojcinski, Bob C. Lin, Ellen Chadwick, IMPAACT P1115 Team. Neutralizing antibody, VRC01, PK and safety among infants initiating very early ART in IMPAACT P1115. Presented at: CROI 2026; 2026 Feb 23.

Citation

Neutropenia, anemia and skin-rash among HIV exposed infants receiving nevirapine and cotrimoxazole compared to cotrimoxazole prophylaxis alone. Presented at: 2nd International Workshop on HIV Pediatrics.

Citation

Mark Mirochnick, M.D., Karin Alvarenga-Hyldgaard Nielsen, M.D., M.P.H., Jose Henrique Pilotto, M.D., Jorge Pinto, M.D., D.Sc., Eleanor Jimenez, M.D., F.A.A.P., Valdilea V. Santos, M.D., Ph.D., Teresa Parsons, Ph.D., Heather D. Watts, M.D., John ( Jack ) Moye, Jr., M.D., Yvonne J. Bryson, M.D. Nevirapine (NVP) pharmacokinetics (PK) with an extended prophylactic regimen during the first two weeks of life. Presented at: 13th Conference on Retroviruses and Opportunistic Infections.

Citation

Paul Palumbo, M.D., Avy Violari, M.D. Nevirapine (NVP) vs lopinavir-ritonavir (LPV/r)-based antiretroviral therapy (ART) in single dose nevirapine (sdNVP)-exposed HIV-infected infants: preliminary results from the IMPAACT P1060 trial. Presented at: 5th IAS Conf on HIV Pathogenesis, TX & Prevention.

Citation

Nevirapine (NVP)- vs. Lopinavir-Ritonavir (LPV/r)-Based Antiretroviral Therapy (ART) among HIV-Infected Infants in Resource-Limited Settings: The IMPAACT P1060 Trial. Presented at: 18th Conference on Retroviruses & Opportunistic Infections.

Citation

John P. Sullivan, M.D. Nevirapine Activity and Emergence of Resistant Virus in Pediatric Trials.

Citation

Mark Mirochnick, Edmund Capparelli, Karin Nielsen-Saines, Jose Henrique Pilotto, Philippa Musoke, Avinash Shetty, Katherine Luzuriaga. Nevirapine Dosing for Treatment in the First Months of Life. Presented at: CROI 2016; 2016 Feb 23.

Citation

Kulkanya Chokephaibulkit, M.D., Tim Roy Cressey, B.Sc., Ph.D., Wasana Prasitsuebsai, M.D., Nirun Vanprapar, M.D., M.Sc., Tawee Chotpitayasunondh, M.D., Koen Frederix, Ram Yogev, M.D., Edmund Capparelli, Pharm.D. Nevirapine exposure in Thai children receiving an adult or pediatric fixed-dose combination of stavudine (d4T), lamivudine (3TC) and nevirapine (NVP). Presented at: 15th Conference on Retroviruses & Opportunistic Infections.

Citation

Edmund Capparelli, Pharm.D., Tim Roy Cressey, B.Sc., Ph.D., David M. Burger, Pharm.D., Ph.D. Nevirapine exposure with WHO Pediatric Weight Band Dosing - enhanced therapeutic concentrations predicted based on extensive international pharmacokinetic experience. Presented at: 15th Conference on Retroviruses & Opportunistic Infections.